Result of EGM

Result of EGM

Eco Animal Health Group Plc

Eco Animal Health Group Plc

(“ECO” or the “Company”)

Result of General Meeting

22 October 2013

The Company announces that at its General Meeting held today, all resolutions put to shareholders were duly passed.

Accordingly, 7,053,385 new ordinary shares are expected to be admitted to trading on AIM at 8.00 am tomorrow, comprising the 6,315,790 shares issued in relation to the placing and the 737,595 shares issued in relation to the exercise of options by certain directors and employees of the Company. The resulting shareholdings of the directors, following admission of the new ordinary shares, are set out in the table below:

Name    

Holding after
exercise and
sale

   

Percentage holding after
exercise and sale of new
shares*

Peter Lawrence

11,373,176

 

18.22%
Brett Clemo 436,948 0.70%
Marc Loomes 1,131,110 1.82%
Kevin Stockdale 370,411 0.60%
Julia Trouse 518,605 0.83%
 

*The vast majority of the shares (2,424,290) in which the Directors (apart from Peter Lawrence) have a beneficial interest are held jointly by the ECO Animal Health Group Employee Benefit Trust and the Director concerned, under the terms of a Joint Share Ownership Plan. These shares do not hold voting rights.

Following the issue of the new ordinary shares the Company’s total issued share capital with voting rights and which is admitted to trading on AIM consists of 62,429,391 ordinary shares of 5p each, with one voting right per share.

Enquiries:

  ECO Animal Health Group plc    
 
Peter Lawrence, Executive Chairman 020 8336 6190
Marc Loomes, CEO 020 8447 8899
 

Spiro Financial

Anthony Spiro 020 8336 6196
 

Cenkos Securities plc (Nominated Adviser)

Stephen Keys 020 7397 8926
Elizabeth Bowman 020 7397 8928
 

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.

UK 100

Latest directors dealings